| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/11/2010 | CA2732901A1 Injectable taxane pharmaceutical composition |
| 02/11/2010 | CA2732887A1 Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists |
| 02/11/2010 | CA2732877A1 Treatment of vaginal atrophy in women with tumor pathology risk |
| 02/11/2010 | CA2732850A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols |
| 02/11/2010 | CA2732828A1 Novel phenylamino isonicotinamide compounds |
| 02/11/2010 | CA2732803A1 Treatment for diabetes in patients inappropriate for metformin therapy |
| 02/11/2010 | CA2732802A1 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 02/11/2010 | CA2732799A1 Modulation of toll-like receptor 7 expression by antisense oligonucleotides |
| 02/11/2010 | CA2732797A1 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/11/2010 | CA2732791A1 Methods of treating thalassemia |
| 02/11/2010 | CA2732788A1 Hyaluronic acid-based gels including lidocaine |
| 02/11/2010 | CA2732765A1 Aminopyridine kinase inhibitors |
| 02/11/2010 | CA2732762A1 Urotensin ii receptor antagonists |
| 02/11/2010 | CA2732682A1 Tripyridyl carboxamide orexin receptor antagonists |
| 02/11/2010 | CA2732582A1 Film-forming liquid formulations for drug release to hair and scalp |
| 02/11/2010 | CA2732526A1 Oxazole derivatives useful as inhibitors of faah |
| 02/11/2010 | CA2732520A1 Therapeutic compounds |
| 02/11/2010 | CA2732226A1 Phosphate binding materials and their uses |
| 02/11/2010 | CA2732211A1 Progestin-containing drug delivery system |
| 02/11/2010 | CA2732165A1 Therapeutic agents 414 |
| 02/11/2010 | CA2732131A1 Compositions and methods for treating psychiatric disorders |
| 02/11/2010 | CA2732105A1 Use of sucralose as a granulating agent |
| 02/11/2010 | CA2732101A1 Aurora kinase modulators and methods of use |
| 02/11/2010 | CA2732093A1 Controlled release formulations using intelligent polymers |
| 02/11/2010 | CA2732087A1 Substituted naphthyridines and their use as medicaments |
| 02/11/2010 | CA2732071A1 Long-term treatment of symptomatic heart failure |
| 02/11/2010 | CA2732045A1 Urea derivatives as antibacterial agents |
| 02/11/2010 | CA2731926A1 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
| 02/11/2010 | CA2731897A1 Diazepine and diazocane compounds as mc4 agonists |
| 02/11/2010 | CA2731520A1 New no-releasing steroids for the treatment of retina and macula lutea diseases |
| 02/11/2010 | CA2731477A1 New no releasing steroids derivatives |
| 02/11/2010 | CA2731368A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 02/11/2010 | CA2731365A1 Tricyclic alkylaminomethyloxazolidinone derivatives |
| 02/11/2010 | CA2731095A1 Compounds useful as inhibitors of protein kinases |
| 02/11/2010 | CA2731041A1 Bupropion hydrobromide polymorphs |
| 02/11/2010 | CA2730715A1 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| 02/11/2010 | CA2730448A1 Inhibitors of iap |
| 02/11/2010 | CA2730064A1 Small molecule inhibitors of retroviral assembly and maturation |
| 02/11/2010 | CA2725012A1 Methods for treating injury associated with exposure to an alkylating species |
| 02/10/2010 | EP2151500A1 Branched -glucan, -glucosyltransferase producing the same, method for producing the same and use thereof |
| 02/10/2010 | EP2151497A2 Chimeric U2 snRNA molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications |
| 02/10/2010 | EP2151466A1 Biologically active silicic acid |
| 02/10/2010 | EP2151454A2 Platelet-derived growth factor D, DNA coding therefor, and uses thereof |
| 02/10/2010 | EP2151448A1 Glycosylate derivatives of mithramycin, method of preparation and uses thereof |
| 02/10/2010 | EP2151447A1 Lincomycin derivatives and antibacterial agents containing the same as the active ingredient |
| 02/10/2010 | EP2151440A1 Heterocyclic compound and use thereof |
| 02/10/2010 | EP2151439A1 Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising the same |
| 02/10/2010 | EP2151438A1 Pharmaceutical containing ppar agonist |
| 02/10/2010 | EP2151437A1 Isoxazoline-substituted benzamide compound and pest control agent |
| 02/10/2010 | EP2151436A1 Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity |
| 02/10/2010 | EP2151435A1 Pharmaceutical composition for treatment of alzheimer's disease |
| 02/10/2010 | EP2151434A1 Alkoxypyrazoles and the process for their preparation |
| 02/10/2010 | EP2151433A1 Alkoxypyrazoles and the process for their preparation |
| 02/10/2010 | EP2151244A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/10/2010 | EP2151242A1 Use of oxygen for treatment of illnesses of the mucous membrane of the intestinal channel |
| 02/10/2010 | EP2151241A1 Stable solid preparation comprising 4,5-epoxymorphinan derivative |
| 02/10/2010 | EP2151240A1 Therapeutic or prophylactic agent for dyskinesia |
| 02/10/2010 | EP2151239A1 A kind of hydrochloric piperphentonamine freeze-dried powder injection, preparation methods and uses thereof |
| 02/10/2010 | EP2151238A1 Diazoxide for the treatment of Friedreich's ataxia |
| 02/10/2010 | EP2151237A1 Pharmaceutical composition combining a non-steroidal anti-inflammatory agent and an anticonvulsant agent |
| 02/10/2010 | EP2151236A1 G-protein-conjugated receptor agonist |
| 02/10/2010 | EP2151235A1 Pharmaceutical formulation for treating the upper digestive tract |
| 02/10/2010 | EP2150554A1 Solvent-free crystalline form of naltrexone |
| 02/10/2010 | EP2150553A1 Condensed heterocyclic compounds as inhibitors of protein kinases |
| 02/10/2010 | EP2150552A1 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| 02/10/2010 | EP2150551A1 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors |
| 02/10/2010 | EP2150550A1 Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| 02/10/2010 | EP2150547A2 Polymorphic forms of bosentan |
| 02/10/2010 | EP2150546A2 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| 02/10/2010 | EP2150543A2 Heterocyclic compounds with affinity to muscarinic receptors |
| 02/10/2010 | EP2150540A2 Method for the production of highly pure 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone), pharmaceutical compositions containing the same, and agent formulations containing tolperisone |
| 02/10/2010 | EP2150539A1 Pyridazinone derivatives |
| 02/10/2010 | EP2150535A2 Pyrazole derivatives as p2x7 modulators |
| 02/10/2010 | EP2150534A1 Isoquinolinone derivatives as nk3 antagonists |
| 02/10/2010 | EP2150530A1 Substituted sulfonamide derivatives |
| 02/10/2010 | EP2150527A2 Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| 02/10/2010 | EP2150525A1 Naphthyl(ethyl) acetamides |
| 02/10/2010 | EP2150265A1 Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism |
| 02/10/2010 | EP2150260A2 Compositions and methods for the treatment of heart failure |
| 02/10/2010 | EP2150257A2 Drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| 02/10/2010 | EP2150256A1 Locally active "soft" antiandrogens |
| 02/10/2010 | EP2150255A1 Quinoxaline derivatives as p13 kinase inhibitors |
| 02/10/2010 | EP2150254A2 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| 02/10/2010 | EP2150253A2 Use of 4-cyclopropylmethoxy-<i>n</i>-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas |
| 02/10/2010 | EP2150252A1 Raf inhibitors for the treatment of thyroid cancer |
| 02/10/2010 | EP2150251A1 Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| 02/10/2010 | EP2150249A2 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine |
| 02/10/2010 | EP2150248A2 Glutamate receptor antagonists and methods of use |
| 02/10/2010 | EP2150246A1 Compositions and methods for treatment of psychiatric disorders |
| 02/10/2010 | EP2150245A1 Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
| 02/10/2010 | EP2150244A1 Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 |
| 02/10/2010 | EP2150243A2 Compositions and methods for enhancing active agent absorption |
| 02/10/2010 | EP2150242A2 Pharmaceutical compositions of duloxetine |
| 02/10/2010 | EP2150241A1 Sustained release microtablets comprising tolterodine tartrate |
| 02/10/2010 | EP2150240A1 Pharmaceutical composition exhibiting improved stability comprising ace inhibitor or pharmaceutically acceptable salt thereof and method for manufacturing thereof |
| 02/10/2010 | EP2150239A1 Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 02/10/2010 | EP2150238A1 Method for the production of adsorbates of a rasagiline salt having a water soluble adjuvant |
| 02/10/2010 | EP2150237A1 Method for the preparation of biocompatible polymeric nanoparticles for drug delivery and nanoparticles prepared thereby |
| 02/10/2010 | EP2150234A1 Stable ophthalmical composition comprising ketotifen and naphazoline and methods of making same |
| 02/10/2010 | EP2150233A1 Liquorice extract antimicrobial and anti-inflammatory isolates |